Significantly increased CCL5/RANTES and CCR7 mRNA levels in localized scleroderma

Area of Science:

• Immunology
• Dermatology
• Connective Tissue Diseases

Background:

• Plaque-type morphea is the most common localized scleroderma (LS) subtype.
• LS is characterized by immune dysregulation, vascular changes, and skin fibrosis.
• Cytokine and chemokine profiles in LS require further investigation.

Purpose of the Study:

• To investigate the expression profiles of cytokines and chemokines in patients with plaque-type morphea compared to healthy controls.
• To identify potential molecular markers and therapeutic targets in localized scleroderma.
• To elucidate the role of specific immune mediators in the pathogenesis of LS.

Main Methods:

• Real-time RT-PCR analysis of skin biopsies from 20 patients with plaque-type morphea and 18 healthy controls.
• Quantification of mRNA expression levels for various cytokines (e.g., IL-6, IL-1α) and chemokines (e.g., CCL5/RANTES, CCR7).
• Statistical analysis to compare gene expression between LS lesions and healthy skin, and to assess correlations.

Main Results:

• Significantly higher median mRNA expression of interleukin-6 (IL-6) was observed in LS lesions compared to healthy skin.
• Median mRNA levels of chemokine ligand 5/RANTES (CCL5/RANTES) and chemokine receptor 7 (CCR7) were significantly increased in LS lesions.
• Conversely, median IL-1α mRNA levels were significantly decreased in LS patients.
• No significant differences in mRNA expression were found for CCL13, IL-1β, IL-2, and tumor necrosis factor-α.

Conclusions:

• The study confirms elevated IL-6 gene expression in localized scleroderma lesions.
• For the first time, significantly increased mRNA levels of CCL5/RANTES and CCR7 are demonstrated in LS, highlighting a key role for these chemokines in LS pathogenesis.
• These findings suggest that CCL5/RANTES and CCR7 may represent important therapeutic targets for plaque-type morphea.